References
1. National institute of infectious diseases. Infectious Agents Surveillance Report. 2021; 42 : 155-67.
2. O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015; 8 : 217-30.
3. Prematunge C, MacDougall C, Johnstone J, et al. VRE and VSE bacteremia outcomes in the era of effective VRE therapy: A systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37 : 26-35.
4. Miller WR, Murray BE, Rice LB, Arias CA. Vancomycin-resistant enterococci: Therapeutic challenges in the 21st century. Infect Dis Clin North Am. 2016; 30 : 415-39.
5. Tacconelli E and Cataldo MA. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents. 2008;31 :99-106.
6. Hayakawa K, Mezaki K, Sugiki Y, et al. High rate of multidrug-resistant organism colonization among patients hospitalized overseas highlights the need for preemptive infection control. Am J Infect Control. 2016; 44 : e257-9.
7. Medina-Polo J, Sopena-Sutil R, Benitez-Sala R, et al. Prospective study analyzing risk factors and characteristics of healthcare-associated infections in a urology ward. Investig Clin Urol. 2017; 58 : 61-9.